Life Stem Genetics Inc. (LIFS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLife Stem Genetics Inc. (LIFS) trades at $0.0001. Life Stem Genetics Inc. is a development-stage biotechnology company focused on establishing a global network of stem cell therapy clinics. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for LIFS: LIFS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Life Stem Genetics Inc. (LIFS) Healthcare & Pipeline Overview
Life Stem Genetics Inc. is a development-stage biotechnology company establishing a global network of stem cell therapy clinics. It offers diverse treatments for degenerative conditions, cancer, and anti-aging, alongside nutraceuticals and stem cell banking, supported by a collaboration with American CryoStem Corporation.
What Is the Investment Thesis for LIFS?
Life Stem Genetics Inc. presents an investment profile centered on its early-stage development within the burgeoning biotechnology sector, specifically regenerative medicine. The company's strategic focus on establishing a global network of stem cell therapy clinics, coupled with a diverse offering of treatments, nutraceuticals, and stem cell banking, positions it to potentially capitalize on the growing interest in advanced medical therapies. Value drivers include the increasing acceptance and research into stem cell applications for a wide range of conditions, from degenerative diseases to anti-aging. The strategic collaboration with American CryoStem Corporation could provide a competitive advantage through shared expertise or resources. However, as a development-stage company, LIFS faces inherent risks associated with early-stage biotech ventures, including the need for substantial capital, potential regulatory hurdles for novel therapies, and the challenges of scaling a global clinic network. Its listing on the OTC Other tier also introduces risks related to limited regulatory oversight and potentially lower liquidity. Future growth catalysts would involve successful clinical advancements, expansion of its clinic footprint, and positive market reception of its therapeutic solutions.
Based on FMP financials and quantitative analysis
LIFS Key Highlights
Market Capitalization: $0.00 billion, reflecting its early-stage development and OTC listing status.
- Dividend Yield: None, consistent with a development-stage company reinvesting any available capital into growth initiatives.
- Strategic Collaboration: Ongoing agreement with American CryoStem Corporation, potentially enhancing its operational capabilities in stem cell services.
- Business Model: Focused on establishing a global network of stem cell therapy clinics, alongside offering nutraceuticals, medical supplements, and stem cell banking services.
- Therapeutic Scope: Provides a broad range of stem cell treatments targeting degenerative conditions, cancer, weight management, anti-aging, and anti-viral applications.
Who Are LIFS's Competitors?
LIFS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.06 | +1.32% | $258M | 90 5-pillar |
| FENC Fennec Pharmaceuticals Inc. | $13.33 | -1.84% | $471M | 91 5-pillar |
| INDP Indaptus Therapeutics, Inc. | $3.13 | -4.86% | $481M | 60 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.07 | -2.26% | $540M | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LIFS's Key Strengths?
Specialized focus on a broad range of stem cell therapies for diverse conditions.
- Comprehensive offering including clinics, nutraceuticals, and stem cell banking.
- Strategic collaborative agreement with American CryoStem Corporation.
- Operating in the high-growth regenerative medicine sector.
What Are LIFS's Weaknesses?
Currently in development phase, indicating limited operational history and revenue.
- Listed on the OTC Other tier, implying limited regulatory oversight and potential liquidity issues.
- High-risk nature inherent to early-stage biotechnology ventures.
- "Unknown" disclosure status, posing transparency challenges for investors.
What Are the Key Risks for LIFS?
Financial-distress signal — its Altman Z-Score of -1.68 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- High-risk nature of early-stage biotechnology ventures, including significant capital requirements and uncertain timelines for product development and market penetration.
- Regulatory hurdles and potential for stringent oversight in the stem cell therapy market, which could delay or prevent commercialization of treatments.
- Limited public disclosure and OTC Other listing, contributing to low liquidity, high volatility, and difficulty in assessing the company's true financial and operational status.
- Intense competition from more established biotechnology firms and research institutions with greater resources and clinical trial experience.
- Challenges in scaling a global network of clinics, including securing necessary licenses, qualified personnel, and patient adoption across different regions.
What Threats Does LIFS Face?
- Intense competition from established biotech and pharmaceutical companies.
- Significant regulatory hurdles and potential for adverse policy changes in regenerative medicine.
- Challenges in securing adequate funding for R&D and global expansion.
- Clinical trial failures or limited efficacy outcomes for therapies.
What Are LIFS's Competitive Advantages?
- Specialized Therapeutic Focus: Concentration on a broad range of stem cell therapies, including Adistem treatments, for specific and complex conditions like orthopedic, neurological, and lung diseases, creates a niche expertise.
- Comprehensive Service Offering: Integration of clinical treatments, nutraceuticals, and stem cell banking provides a holistic approach to health and regenerative medicine, potentially increasing patient engagement and loyalty.
- Strategic Collaboration: The agreement with American CryoStem Corporation may offer access to proprietary technologies, research, or operational efficiencies, providing a competitive edge in the highly specialized field of cryopreservation and stem cell application.
- Early-Mover Advantage in Clinic Network: While in development, the stated goal of establishing a global network of specialized clinics could position LIFS to capture market share in regions where advanced stem cell therapies are in high demand but clinic access is limited.
What Does LIFS Do?
Life Stem Genetics Inc., founded in 2012 and headquartered in Beverly Hills, California, is a biotechnology enterprise currently in its development phase. The company's core strategic objective is to establish a global network of specialized clinics dedicated to advanced stem cell therapy. Its comprehensive portfolio extends beyond clinical treatments to include a range of nutraceuticals, medical supplements, and intravenous nutritional cocktails designed to support overall health and regenerative processes. A significant component of its service offering is stem cell banking, providing individuals with the opportunity to preserve their own stem cells for potential future therapeutic use. Life Stem Genetics Inc. offers a variety of stem cell treatments targeting a broad spectrum of health concerns, including degenerative conditions, various forms of cancer, and weight management programs. Additionally, the company provides anti-aging and anti-viral therapies, leveraging the regenerative potential of stem cells. A key aspect of its therapeutic approach involves Adistem stem cell treatments, specifically tailored for orthopedic, neurological, and lung diseases. Complementing these stem cell therapies, Life Stem Genetics Inc. also offers hyperbaric oxygen therapy, a treatment known for its potential to enhance healing and recovery. The company maintains a strategic collaborative agreement with American CryoStem Corporation, which could provide access to specialized technologies or expertise in the cryopreservation and application of stem cells, further solidifying its position in the evolving regenerative medicine landscape. Operating from East Stroudsburg, US, the company is focused on advancing its clinic network and therapeutic offerings.
What Products and Services Does LIFS Offer?
- Establishes and operates a global network of specialized stem cell therapy clinics.
- Provides a variety of stem cell treatments for degenerative conditions, cancer, and weight management.
- Offers anti-aging and anti-viral stem cell therapies.
- Delivers Adistem stem cell treatments specifically for orthopedic, neurological, and lung diseases.
- Provides hyperbaric oxygen therapy as a complementary treatment.
- Sells nutraceuticals, medical supplements, and intravenous nutritional cocktails.
- Offers stem cell banking services for cryopreservation and future therapeutic use.
- Maintains a strategic collaborative agreement with American CryoStem Corporation.
How Does LIFS Make Money?
- Generates revenue from fees for stem cell therapy treatments and related medical services provided at its clinics.
- Earns income from the sale of nutraceuticals, medical supplements, and intravenous nutritional cocktails.
- Receives fees for stem cell banking services, including initial processing and ongoing storage.
- Potentially benefits from collaborative agreements, which may involve shared intellectual property or revenue streams.
What Industry Does LIFS Operate In?
Life Stem Genetics Inc. operates within the dynamic and rapidly evolving biotechnology sector, specifically targeting the regenerative medicine and stem cell therapy market. This industry is characterized by significant scientific innovation, high research and development costs, and stringent regulatory pathways. The global stem cell therapy market is projected to experience substantial growth, driven by increasing prevalence of chronic diseases, advancements in stem cell research, and rising demand for personalized medicine. LIFS's strategy of establishing a network of clinics and offering a diverse suite of related products positions it to address various segments of this market, from direct patient care to preventative health and cell banking. The competitive landscape includes established pharmaceutical companies, specialized biotech firms, and academic institutions, all vying for market share in therapeutic development and clinical application. As a development-stage company, LIFS aims to carve out its niche by focusing on comprehensive service offerings and strategic partnerships, such as its collaboration with American CryoStem Corporation, to differentiate itself in a crowded and capital-intensive industry.
Who Are LIFS's Key Customers?
- Patients seeking treatment for degenerative conditions, including orthopedic, neurological, and lung diseases.
- Individuals undergoing cancer treatment or seeking complementary therapies.
- Clients interested in anti-aging and anti-viral therapies.
- Individuals seeking weight management solutions through stem cell applications.
- Health-conscious consumers purchasing nutraceuticals, medical supplements, and nutritional cocktails.
- Individuals and families opting for long-term stem cell banking services.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Life Stem Genetics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in East Stroudsburg, US. The company is led by CEO Gloria Simov. LIFS has traded publicly since 2013.
Financial Health
Life Stem Genetics Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.68 places it in the distress zone, a signal of elevated financial risk.
LIFS Latest News
No recent news available for LIFS.
LIFS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LIFS.
Price Targets
Wall Street price target analysis for LIFS.
LIFS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LIFS; grades run from A+ (80-100) to F (below 30).
Leadership: Gloria Simov
Chief Executive Officer
Gloria Simov serves as the Chief Executive Officer of Life Stem Genetics Inc., guiding the company through its critical development phase within the biotechnology sector. Her position involves overseeing the strategic direction, operational development, and collaborative initiatives crucial for a nascent enterprise in regenerative medicine.
Track Record: Under Gloria Simov's leadership, Life Stem Genetics Inc. has progressed in its stated mission to establish a global network of stem cell therapy clinics. A notable achievement includes the formation of a strategic collaborative agreement with American CryoStem Corporation, a key partnership for a company operating in specialized medical services. Her tenure is focused on laying the foundational elements for the company's future growth and market penetration in the stem cell therapy domain.
LIFS OTC Market Information
Life Stem Genetics Inc. trades on the OTC Other tier, which represents the lowest and most speculative category within the OTC Markets Group's three tiers (OTCQX, OTCQB, and OTC Other). Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and public disclosure, companies on the OTC Other tier have minimal to no reporting requirements. This tier typically includes shell companies, defunct entities, or companies with limited public information, making it a high-risk environment for investors due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited Public Information: "Unknown" disclosure status means investors lack critical financial and operational data for informed decisions.
- Minimal Regulatory Oversight: OTC Other companies are subject to significantly less scrutiny compared to major exchanges, increasing the risk of fraud or mismanagement.
- Low Liquidity and Volatility: Very low trading volume and wide bid-ask spreads can make shares difficult to trade, leading to potential significant price swings.
- Difficulty in Valuation: Lack of reliable financial reporting makes it extremely challenging to accurately value the company or its prospects.
- Potential for Penny Stock Fraud: OTC Other tier is often associated with "pump and dump" schemes due to low transparency and ease of manipulation.
- Verify any available financial statements, even if unaudited, for consistency and red flags.
- Research the background and track record of management beyond provided names.
- Investigate the legitimacy and operational status of its stated global clinic network.
- Confirm the specifics and current status of the collaborative agreement with American CryoStem Corporation.
- Scrutinize any public announcements or press releases for verifiable facts and progress.
- Assess the regulatory environment for its specific stem cell therapies and potential hurdles.
- Understand the company's funding status and capital requirements for its development phase.
- Established in 2012, indicating some operational longevity, albeit in a development phase.
- Stated focus on a specific, high-potential sector (stem cell therapy and regenerative medicine).
- Maintains a strategic collaborative agreement with American CryoStem Corporation, suggesting a verifiable external partnership.
- Identified CEO, Gloria Simov, provides a named individual responsible for leadership.
LIFS Healthcare Stock FAQ
What revenue streams does Life Stem Genetics Inc. have in healthcare?
Life Stem Genetics Inc. aims to generate revenue through multiple streams within the healthcare sector, reflecting its diverse business model.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based solely on provided source data. Details on CEO background, financial performance beyond market cap, and specific operational metrics are limited.